Table of Contents

Table of Contents

To our teammates’ commitment to care for patients with kidney disease. The ongoing COVID-19 pandemic created challenges that we could never have imagined at the beginning of 2020. These challenges – clinical, operational and financial – led to opportunities for us to harness the strength of our teams and our platforms to support our patients and our community in this time of global crisis. When I reflect on the year, I am inspired by the resilience, creativity and innovation showed by our organization to adapt to the unprecedented and rapidly changing landscape and by the depth of the empathy and commitment of our teams to each other and to the health and safety of our patients.

Over the past year, we took significant steps to enhance our infection control and safety practices and create new processes, such as the early cohorting of patients with suspected or confirmed cases of COVID-19, to ensure that we could continue to provide high-quality carestockholders, thank you for the more than 240,000 patients who depend on receiving life-sustaining dialysis treatment from us multiple times each week.

Earlier this year, the dialysis community came together with the CDCtrust, confidence and federal government to launch a national program to allocate COVID-19 vaccines directly to dialysis providers for the vaccination of end-stage renal disease patients and their front-line caregivers, an important policy by the administration to protect some of the nation’s most vulnerable patients. We continue to work hard to implement this program to help ensure that all of our patients who want to be vaccinated can receive a vaccine as soon as possible. Across the U.S., COVID-19 vaccination rates for Blacks and Hispanics remain well below that of Whites and Asians. We have been able to deploy our care teams, including social workers and dietitians, to engage in one-on-one conversations to address common causes of vaccine hesitancy, with support from our Medical Directors. We believe these efforts, combined with offering patients direct access to the vaccine from a trusted care team and in a convenient site of care, have addressed the challenges with third-party sites, reduced hesitancy rates and improved health equity.

At DaVita we have a long history of investing in the development and well-being of our teammates. Through the pandemic, we increased this investment in caring for our own teammates, including providing tens of millions of dollars in relief payments to eligible teammates, adjusting pay and paid time off practices to better support our teammates and enhancing benefits, including backup child care and free counseling and mental health resources.

While caring for our patients and teammates, we have continued to focus on stewarding resources responsibly to deliver financial results for our stockholders.

Last year at this time, I shared with you how inspiring our 67,000 teammates around the world are, especially our caregiving teammates and physician partners. A year later, I feel even more strongly that our caregivers on the front line of this pandemic are heroes in every sense of the word. I thank them for their selfless service. Their courage, compassion and dedication honor the memory of those we have lost to the pandemic.

Very truly yours,

Javier J. Rodriguez
Director and Chief Executive Officer

---

Table of Contents

April 23, 2021

Dear Fellow Stockholders:

I am proud to serve you as Chair of your Board of Directors and to share our accomplishments of the past year. I must start by acknowledging how proud your Board is of our teammates’ response to the unprecedented and extraordinary challenges presented by the global COVID-19 pandemic. Our caregivers have demonstrated the highest levels of resiliency, perseverance and innovation as they have continued to provide life-sustaining services to our patients.

At DaVita, we are committed to continuing to deliver on strong governance and responsible corporate citizenship, and being responsive to all stakeholders. In particular, I would like to highlight the following ways the Board and management have been working on your behalf.

Thoughtful Approach to Board Composition with a Demonstrated Commitment to Refreshment and Diversity.

Your Board is committed to maintaining a balanced and effective Board with a broad mix of tenure, skills, experience and diversity of backgrounds and viewpoints. In 2020 we appointed two new independent directors to the Board, Shawn Guertin and Paula Price, who add to the richness of experience of your Board. Mr. Guertin is the former Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer of Aetna, Inc., and Ms. Price is the former Executive Vice President and Chief Financial Officer of Macy’s, Inc. In addition, your Board has an average tenure of 8.2 years, and we are proud of the fact that it is comprised of 44% women and 33% people of color.

Ongoing Dialogue with Stockholders through Robust Engagement that Includes Independent Directors.

We believe that engaging with stockholders is fundamental to our commitment to good governance, and since our 2020 Annual Meeting of Stockholders, some combination of management and the Chair of our Compensation Committee met with stockholders representing approximately 64% of DaVita's outstanding shares. Over the past several years, feedback received from these discussions has helped inform changes to our executive compensation program and further improve our disclosures. Some of this year’s enhancements resulting from these discussions include changes to our compensation practices that require above median TSR performance for executives to receive target level PSU vesting and enhancing the linkage between DaVita’s ESG performance and executive pay. In addition, after consideration of feedback from stockholders, we have further enhanced our political and lobbying spending disclosures and have committed to additional semi-annual reporting regarding the company’s political and lobbying spend to begin in July of this year.

Commitment to Corporate Social Responsibility.

The Board’s Nominating and Governance Committee oversees DaVita’s policies and programs related to corporate, environmental and social responsibility. Being a responsible corporate citizen has long been an important principle at DaVita. Since 2008, we have published an annual social responsibility report we call Community Care, highlighting our organization’s and teammates’ contributions and support of the communities in which we live and operate. A shining example of supporting our communities was the decision by our Board and management to return approximately $250 million of CARES Act funding so that government support and funding could be used by those organizations in greater need than us.

In 2019 and 2020, our company surveyed key stakeholders to learn more about what ESG issues matter most to them and also reviewed the Sustainability Accounting Standards Board ("SASB") recommended metrics for health care service providers. Based, in part, on these data sources, our company has identified our top ESG priorities and five key focus areas, and we will be publishing a set of aspirational goals for 2025 across each of the pillars of our ESG program. Furthermore, we recognize that the latest climate science sends a warning that we must dramatically curb temperature rise to avoid the impacts of climate change, and as a company, we want to do our part. Accordingly, we have presented our environmental goals for 2025 and beyond to the Science Based Targets initiative for their review and confirmation that our goals are in alignment with climate science.

In spring 2021, for the first time we will publish our ESG report based on the recommendations from SASB and its material topics for health care service providers. We also published our first report on Diversity and Belonging, disclosing our company’s diversity metrics and a roadmap for delivering our vision of cultivating a diverse organization where everyone belongs.

We are tremendously proud of our ongoing efforts in sustainability and social responsibility. To learn more, I encourage you to read our 2020 Community Care social responsibility report at www.davita.com/communitycare.

---

Table of Contents

In closing, I would like to say a special thank you to our stockholders. We recognize and greatly appreciate the trust and confidence you have placed in us. We willgreatly appreciate your feedback and support, as we continue to represent your interests throughwork to meet the needs of our strong independent oversight of management.

On behalf of your Board of Directors,

Pamela M. Arway
patients at every step along their kidney health journey.

Javier J. Rodriguez						Pamela M. Arway
Director and Chief Executive Officer						Chair of the Board

By order of the Board of Directors,

Samantha A. Caldwell
Corporate Secretary
April 23, 2021

---

Table of Contents

Samantha A. Caldwell
Corporate Secretary

We outperformed the high end of the guidance metrics set forth below that were provided to investors in our fourth quarter 2019 earnings release other than with respect to revenue, and we performed at the midpoint of our revenue guidance range.^{1, 2}

We outperformed expectations provided at beginning of year on most metrics despite unknown COVID-19 headwinds when guidance was issued.

(1) The graphic contains non-GAAP financial measures. Please see Annex A for a presentation of the most directly comparable GAAP financial measure and a reconciliation of the non-GAAP financial measure to the most directly comparable GAAP financial measure.

(2) In 2020, we also met expectations with respect to effective income tax rate on adjusted income from continuing operations attributable to DaVita Inc. and maintained our disciplined approach to capital efficient growth by coming in below the guided range for capital expenditures from continuing operations.

(3) "External Guidance" as presented in the graphic refers to selected 2020 guidance measures provided to investors on February 10, 2020 with our earnings results for the year ended December 31, 2019.

Table of Contents

DaVita has been on the front line of the COVID-19 pandemic, as a caregiving organization that needs to keep its doors open to provide life-sustaining care to its patients. During this time of great challenge, our top priorities continue to be the health, safety and well-being of our patients, teammates and physician partners. To that end, we have dedicated and continue to dedicate substantial resources in response to COVID-19:

COVID-19 Relief for Teammates

Relief payments, primarily to frontline teammates		Free counseling & mental health resources		Access to Paid Time Off (PTO) advances and lifted PTO accrual caps for eligible teammates		Back-up child care

COVID-19 Relief for Patients and Communities

Continued to provide life-sustaining therapy to ~200,000 domestic dialysis patients in the face of the crisis		Enhanced our already-robust infection control processes		Secured appropriate PPE to maintain protocols that meet or exceed CDC guidelines		Provided outpatient dialysis to ~75% of our patients with suspected or confirmed COVID-19 to help reduce burdens on hospitals

The following sets forth a summary of information about our Board of Directors ("Board") and corporate governance program. See "— Board of Directors Information" for additional information about our Board and "—Corporate Governance" for additional information about our corporate governance program.

Independent, Female Board Chair	Three of Four Committee Chairs are Diverse
Pamela Arway	Phyllis Yale	Barbara Desoer	Paul Diaz	Shawn Guertin
Independent	Chair, Nominating &	Chair, Compensation	Chair, Compliance &	Chair, Audit
Board Chair	Governance Committee	Committee	Quality Committee	Committee

2

Notice of 2021 Annual Meeting and Proxy Statement

Table of Contents

*Director nominees
**Under NYSE Independence Standards

*Diversity and Tenure calculations are as of April 23, 2021.

Engaging with investors to solicit feedback on matters of interest to them is fundamental to our commitment to good governance. In 2020, we continued our robust year-round stockholder engagement efforts and met with investors representing approximately 64% of our outstanding shares.	Outreach	Engagement	Committee Chair Participation

Key Items Discussed with Stockholders in 2020 and 2021

	Corporate Governance			Executive Compensation			Corporate Responsibility
Board Leadership and Succession Planning			Pay-for-Performance			Political Spending Disclosure
Board Tenure and Refreshment			CEO Compensation			Workforce Development and Diversity
Board Diversity			Long-Term Incentive Compensation			Sustainability

Table of Contents

Stockholder Feedback Helped Shape 2021 Executive Compensation Program

CEO 2020 Total Direct Compensation

Our CEO's 2020 Total Direct Compensation, which is defined as salary received during the year, annual cash performance bonus (or short-term incentive) earned for a year (and paid early the following year) and annualized grant date fair market value of long-term incentives (equity) awarded that year, is set forth below. The Annual Long-Term Incentive Award ("Annual LTI Award") shown reflects an annualized value calculated as 20% of the actual grant date fair value of the CEO Premium-Priced SSAR Award because that award is intended to replace five years of long-term incentive awards. For additional details on our CEO's compensation, see "— Compensation Discussion & Analysis — Executive Summary — CEO Premium-Priced SSAR Award."

4

Notice of 2021 Annual Meeting and Proxy Statement

Table of Contents

Having ESG as a priority is not new to DaVita. Our Trilogy of Care – Caring for Our Patients, Caring for Each Other, and Caring for Our World – has been at the heart of what we do for more than 15 years.

The Nominating and Governance Committee of DaVita’s Board oversees DaVita’s activities, policies and programs related to ESG. The management ESG Steering Committee provides guidance on strategy and disclosures for our ESG initiatives.

DaVita's ESG Areas of Focus

For more information on our 2025 ESG goals, organized around the following key topics, visit our Community Care website at www.davita.com/communitycare. Website references throughout this Proxy Statement are provided for convenience only, and the content on the referenced websites is not incorporated by reference into this Proxy Statement.

Patient Care			Diversity and Belonging			Commitment to 100% Renewable Energy
96% of facilities scored 3, 4 or 5 stars in CMS’s Five Star Quality Rating System, more than any other dialysis provider. Realizable Pay			As an organization that is 78% women and 54% teammates of color, we are working to ensure strong representation of women and people of color at all levels in our organization.			By 2022, DaVita’s agreements to purchase energy from wind and solar farm developments in Texas are expected to create as much clean energy annually as the amount of electricity we use to operate our U.S. centers.

Table of Contents

We are delivering this Proxy Statement in connection with the solicitation of proxies by the Board of Directors (the “Board”) of DaVita Inc. ("DaVita" or the "Company"), for use at our 2021 Annual Meeting of Stockholders (the “Annual Meeting”), which will be held on Thursday, June 10, 2021 at 10:00 a.m. Mountain Time. The Annual Meeting will be a live audio webcast available at www.virtualshareholdermeeting.com/DVA2021, where you will be able to attend, vote your shares electronically and submit questions. We are committed to ensuring that stockholders will be afforded the same rights and opportunities to participate in our virtual meeting as they would at an in-person meeting.

The proxies solicited for the Annual Meeting will remain valid for use at any meetings held upon adjournment or postponement thereof by the presiding person of the Annual Meeting. The record date for the Annual Meeting is the close of business on April 13, 2021 (the "Record Date"). All holders of record of the Company's common stock ("Common Stock") on the Record Date are entitled to notice of the Annual Meeting and to vote at the Annual Meeting and any meetings held upon adjournment or postponement of that meeting by the presiding person of the Annual Meeting.

To participate in the virtual Annual Meeting, you will need the 16-digit control number included on your Notice of Internet Availability of Proxy Materials ("e-proxy notice"), proxy card or voting instruction form. The audio webcast will begin promptly at 10:00 a.m. Mountain Time. Online check-in will begin at 9:45 a.m. Mountain Time, and you should allow ample time for the check-in procedures. If you encounter any technical difficulties with the virtual meeting platform on the meeting day, please call the technical support number that will be posted on the Annual Meeting log in page at www.virtualshareholdermeeting.com/DVA2021.

If you wish to submit a question during the Annual Meeting, log into the virtual meeting platform beginning at 9:45 a.m. Mountain Time on the meeting day, type your question into the “Ask a Question” field, and click “Submit.” We intend to answer questions submitted by stockholders during the Annual Meeting that comply with the Annual Meeting rules of conduct, which will be posted on the virtual meeting platform.

We are using the "e-proxy" rules adopted by the U.S. Securities and Exchange Commission (the “SEC”) to furnish proxy materials to our stockholders over the Internet. Under the e-proxy rules, the e-proxy notice will be mailed on or about April 23, 2021 to our stockholders of record and beneficial owners of our Common Stock as of the Record Date, in lieu of a printed copy of our proxy materials. We believe using this e-proxy notice model allows us to reduce costs and helps reduce our carbon footprint.

If you receive an e-proxy notice by mail, you will not receive a printed copy of the proxy materials unless you have previously made a permanent election to receive these materials in paper copy. The e-proxy notice provides instructions on how you may access and review our proxy materials, including this Proxy Statement, the accompanying Notice of 2021 Annual Meeting of Stockholders and the Company's 2020 Annual Report to Stockholders, as well as instructions on how you may submit your vote. If you received an e-proxy notice by mail and would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting such materials included in the e-proxy notice.

Whether or not you plan to virtually attend the Annual Meeting, we encourage you to vote prior to the Annual Meeting by telephone, Internet, or by requesting a proxy card to complete, sign, date and return by mail. Voting in advance will help ensure that your shares will be voted at the Annual Meeting.

6

Notice of 2021 Annual Meeting and Proxy Statement

Table of Contents

Unless you instruct otherwise in your proxy, any proxy that is given and not revoked will be voted at the Annual Meeting:

Our only voting securities are the outstanding shares of our Common Stock. As of the Record Date, we had approximately 106,612,581 shares of Common Stock outstanding. Each stockholder is entitled to one vote per share on each matter that we will consider at the Annual Meeting. Stockholders are not entitled to cumulate votes. Under the rules of the New York Stock Exchange (“NYSE”), your broker, bank or other nominee may not vote your uninstructed shares in the election of directors and certain other matters on a discretionary basis. Accordingly, brokers holding shares of record for their customers generally are not entitled to vote on these matters unless their customers give them specific voting instructions. If the broker does not receive specific instructions, the broker will note this on the proxy form or otherwise advise us that it lacks voting authority. Thus, if you hold your shares in “street name,” meaning that your shares are registered in the name of your broker, bank or other nominee, and you do not instruct your broker, bank or other nominee how to vote, no votes will be cast on your behalf on any proposal other than the proposal for the ratification of the appointment of KPMG LLP as our independent registered public accounting firm for fiscal year 2021. The votes that the brokers would have cast if their customers had given them specific instructions are commonly called “broker non-votes.” If the stockholders of record present at the Annual Meeting or represented by their proxies and entitled to vote at the Annual Meeting hold at least a majority of our shares of Common Stock outstanding as of the Record Date, a quorum will exist for the transaction of business at the Annual Meeting. Stockholders virtually attending the Annual Meeting or represented by proxy at the Annual Meeting who abstain from voting and broker non-votes are counted as present for quorum purposes. We will make a list of stockholders as of the Record Date available electronically during the Annual Meeting on the virtual meeting website, and during the ten days prior to the Annual Meeting you may contact Investor Relations at 1-888-484-7505 to request the list of stockholders as of the Record Date.

Stockholders

Shares of our Common Stock may be held directly in your own name or may be held beneficially through a broker, bank or other nominee in "street name." We have summarized below the distinctions between shares held of record and those owned beneficially.

Stockholder of Record — If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A., you are considered the stockholder of record with respect to those shares and we are providing proxy materials directly to you. As the stockholder of record, you have the right to vote online during the Annual Meeting or to grant your voting proxy to the persons designated by us or a person you select.

Beneficial Owner — If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the beneficial owner of the shares held in "street name," and you have been provided proxy materials

Table of Contents

from your broker, bank or other nominee who is considered the stockholder of record with respect to the shares. As the beneficial owner, you have the right to direct the broker, bank or nominee on how to vote your shares and are also invited to virtually attend the Annual Meeting. Your broker, bank or nominee is obligated to provide you with a voting instruction form for you to use. This voting instruction form will also include a 16-digit control number that will allow you to access the Annual Meeting audio webcast and vote your shares during the Annual Meeting. For additional information regarding attending and voting at the Annual Meeting, see the information under the heading “—General Information.”

Voting

Whether you hold our shares as a stockholder of record or as a beneficial owner, you may vote before the Annual Meeting. Most stockholders will have a choice of voting through the Internet or by telephone or, if you received a printed copy of the proxy materials, by completing a proxy card or voting instruction form and returning it in a postage-prepaid envelope. Please refer to the instructions below and in the e-proxy notice. If you are a Company employee, or "teammate," who holds shares of Common Stock through the DaVita Retirement Savings Plan (the "401(k) Plan"), certain earlier voting deadlines apply.

Teammate 401(k) Stockholders — If you participate in the 401(k) Plan and you are invested in our Common Stock fund in your account, you may give voting instructions to the 401(k) Plan trustee, Voya Institutional Trust (the "plan trustee"), as to the number of shares of Common Stock equivalent to the interest in our Common Stock fund credited to your account as of the most recent valuation date coincident with or preceding the Record Date. The plan trustee will vote your shares in accordance with your instructions received by June 7, 2021 at 11:59 p.m. Eastern Time. You may also revoke previously given voting instructions by June 7, 2021 at 11:59 p.m. Eastern Time, by filing with the plan trustee either written notice of revocation or a properly completed and signed voting instruction form bearing a later date. If you do not send instructions for a proposal, the plan trustee will vote the number of shares equal to the share equivalents credited to your account in the same proportion that it votes shares for which it did receive timely instructions.

Changing Your Vote — If you are a stockholder of record or beneficial owner, you may change your vote at any time prior to the applicable voting deadline with your 16-digit control number. If you virtually attend the Annual Meeting you will also be given the opportunity to vote or change your vote during the Annual Meeting through the virtual meeting platform at: www.virtualshareholdermeeting.com/DVA2021.

Through the Internet				Prior to the Annual Meeting, you may vote through the Internet by going to www.proxyvote.com and following the instructions. You will need to have the e-proxy notice, or if you received a printed copy of the proxy materials, your proxy card or voting instruction form, available when voting through the Internet. If you want to vote through the Internet, you must do so prior to 11:59 p.m., Eastern Time, on Wednesday, June 9, 2021. If you vote through the Internet, you do not need to return a proxy card. During the Annual Meeting, you may vote through the Internet by following the instructions at www.virtualshareholdermeeting.com/DVA2021. You will need to have your e-proxy notice, proxy card or voting instruction form available when you access the virtual Annual Meeting web page. 80
By Telephone				You may vote by touch tone telephone by calling 1-800-579-1639. You will need to have your e-proxy notice, or if you received a printed copy of the proxy materials, your proxy card or voting instruction form, available when voting by telephone. If you want to vote by telephone, you must do so prior to 11:59 p.m., Eastern Time, on Wednesday, June 9, 2021. If you vote by telephone, you do not need to return a proxy card.
By Mail		If you are a beneficial owner, you may vote by mail by signing and dating your voting instruction form provided by your broker, bank or nominee and mailing it in a postage-prepaid envelope. If you are a stockholder of record and you received a printed copy of our proxy materials, you may vote by signing and dating your proxy card and mailing it in a postage-prepaid envelope. If you are a stockholder of record and received the e-proxy notice, in order to obtain a proxy card, please follow the instructions on the e-proxy notice. If you want to vote by mail, the proxy card or voting instruction form must be received prior to 11:59 p.m. Eastern Time, on Wednesday, June 9, 2021.

8

Notice of 2021 Annual Meeting and Proxy Statement

Table of Contents

The table below details the proposals to be voted on at the Annual Meeting, the Board's recommendation on how to vote on each proposal, the votes required to approve each proposal and the effect of abstentions and broker non-votes.

The Company pays the cost of preparing, assembling, printing and mailing to our stockholders the e-proxy notice, this Proxy Statement and the accompanying Notice of Annual Meeting, and the Annual Report to Stockholders, as well as the cost of our solicitation of proxies relating to the Annual Meeting. We may request banks and brokers to solicit their customers who beneficially own our Common Stock. We will reimburse these banks and brokers for their reasonable out-of-pocket expenses relating to these solicitations. We have also retained MacKenzie Partners, Inc. (“MacKenzie”) to assist in the distribution and solicitation of proxies and to verify records related to the solicitation at a fee of $16,000, plus reimbursement for all reasonable out-of-pocket expenses incurred during the solicitation. MacKenzie and our officers, directors and teammates may supplement the original solicitation by mailing of proxies, by telephone, e-mail and personal solicitation. We have agreed to indemnify MacKenzie against liabilities and expenses arising in connection with the proxy solicitation unless caused by MacKenzie’s gross negligence, willful misconduct or bad faith.

The general corporate governance framework for DaVita Inc. (the "Company") is set by its Amended and Restated Bylaws (the "Bylaws"), Corporate Governance Guidelines, the charters for each of the e-proxy noticeCommittees of our Board of Directors (the "Board"), the Code of Ethics and as applicable, an Annual Report to Stockholders and Proxy Statement (collectively, the "Proxy Materials"), unless their broker has received contrary instructions from any beneficial ownerCode of Conduct. Each of these governance documents is available under the Corporate Governance section of our website, located at that address. This practice, known as “householding,” is designed to reduce printing and mailing costs for DaVita. If any beneficial owner at such an address wishes to discontinue householding and receive a separate copy of the Proxy Materials, they should notify their broker. Beneficial owners sharing an address to which a single copy of the Proxy Materials was delivered can also request prompt delivery of a separate copy of the Proxy Materials by contacting Investor Relations at the following address or phone number: DaVita Inc., Attn: Investor Relations, 2000 16th Street, Denver, Colorado 80202, 1-888-484-7505. Additionally, stockholders who share the same address and receive multiple copies of the Proxy Materials can request a single copy by contacting us at the address or phone number above.

10

Notice of 2021 Annual Meeting and Proxy Statement

---

www.davita.com/about/corporate-governance.

Table of Contents

Table of Contents

A biography of each director nominee, current as of April 23, 2021,25, 2023, setting forth his or her age, and describing his or her business experience during the past five years, including other prior relevant business experience, is presented below.

Former President of the Japan, Asia-Pacific, Australia Region, American Express International, Inc. Independent Director Since: 2009 Independent Board Chair Since: 2020 Committee Service: Compensation Committee; Nominating and Governance Committee Other Public Company Boards: —The Hershey Company (NYSE: HSY) —Iron Mountain Inc. (NYSE: IRM)						Pamela M. Arway, 67,69, served as the President of the Japan, Asia-Pacific, Australia region for American Express International, Inc., a global payment services and travel company, from 2005 to 2008. Ms. Arway joined the American Express Company in 1987, and subsequently served in various capacities, including as Chief Executive Officer ("CEO") of American Express Australia Limited from 2004 to 2005 and as Executive Vice President of Corporate Travel, North America from 2000 to 2004. Prior to her retirement in October 2008, she also served as advisor to the American Express Company’s Chairman and CEO. Since May 2010, Ms. Arway has been a member of the Board of Directors of The Hershey Company, a chocolate and confectionery company, and since March 2014, Ms. Arway has been a member of the Board of Directors of Iron Mountain Incorporated, an enterprise information management services company. Ms. Arway brings significant leadership experience as a global executive, with extensive management experience in the areas of marketing, international business, finance and government affairs. With her service as a director on the boards of other large public companies, Ms. Arway also brings significant experience in corporate governance and executive compensation relatedcompensation-related matters.

Former Executive Chair, DaVita Medical Senior Advisor, The Cigna Group Independent Director Since: 2022 Director Since:2007 Committee Service: Compliance and Quality Committee

Charles G. Berg, 63,65, has served as a Senior Advisor for The Cigna Group (“Cigna”), a global health service company, since January 2023, and served as President of U.S. Government Business and Senior Advisor for Cigna from January 2022 to January 2023. Mr. Berg served as Executive Chair of DaVita Medical Group ("DMG"), DaVita's former integrated healthcare business, from November 2016 until December 2017. From 2008 to 2013, Mr. Berg served as Executive ChairmanChair of WellCare Health Plans, Inc. (“WellCare”), a provider of managed care services for government-sponsored healthcare programs. Mr. Berg served as Non-Executive ChairmanChair of the Board of Directors of WellCare from January 2011 until his retirement in May 2013. From January 2007 to April 2009, Mr. Berg was a Senior Advisor to Welsh, Carson, Anderson & Stowe, a private equity firm. From April 1998 to July 2004, Mr. Berg held various executive positions, including Executive Vice President - Medical Delivery, President and Chief Operating Officer ("COO") with Oxford Health Plans, Inc. (“Oxford”), a health benefit plan provider. He was the CEO when Oxford was acquired by UnitedHealth Group. He then became an executive of UnitedHealth Group and was primarily responsible for integrating the Oxford business. Mr. Berg also currently serves as a member of the Operating Council & Senior Advisory Board of Consonance Capital Partners, a private equity firm. Mr. Berg is an experienced business leader with significant experience in the healthcare industry and brings an understanding of the operational, financial and regulatory aspects of our industry and business.

12
			Notice of 20212023 Annual Meeting and Proxy StatementStatement			2

Former Chief Executive Officer, Citibank, N.A. Independent Director Since: Since: 2015 Independent Committee Service: Compensation Committee, Chair; Compliance and QualityAudit Committee Other Public Company Boards: —Citigroup Inc. (NYSE: C)

Barbara J. Desoer, 68,70, served as the CEO and a member of the Board of Directors of Citibank, N.A., a wholly owned subsidiary of Citigroup, Inc., a diversified global financial services company, both positions she held from April 2014 through April 2019, and COO of Citibank, N.A. from October 2013 to April 2014. Prior to Citibank, N.A., Ms. Desoer spent 35 years at Bank of America, a diversified global financial services company, most recently as President, Bank of America Home Loans, where she led the integration of Countrywide, the largest mortgage originator and servicer in the United States. In previous Bank of America roles, Ms. Desoer served as a Global Technology & Operations executive, an international market-focused position leading teams in the United Kingdom, Asia and Latin America, and President, Consumer Products. Since April 2019, Ms. Desoer has served as Chair of Citibank, N.A. and as a member of the Board of Directorsdirector of Citigroup, Inc. She serves on the Board of Visitors at the University of California at Berkeley and on the Advisory Board of InStride. Ms. Desoer also has served on the board of directors of various non-profit and privately held corporations. Ms. Desoer is an experienced business leader with extensive management and international experience, and brings a deep understanding of regulated businesses.

President and Chief Executive Officer, Myriad Genetics,Cardinal Health, Inc. Independent Director Since: 2007 Independent Since: 2022 Committee Service: Compliance and QualityAudit Committee, Chair; Compensation Committee Chair* Other Public Company Boards: —Myriad Genetics,Cardinal Health, Inc. (NASDAQ: MYGN)(NYSE: CAH)						Paul J. DiazJason M. Hollar, 59,50, has served as the President, CEO and a member of the Board of Directors for Myriad Genetics,of Cardinal Health, Inc., a molecular diagnostic company since August 2020. From September 2017 to August 2020, Mr. Diaz was a Partner at Cressey & Company LP, a private equity firm focused exclusively on investing in and building health care businesses, and currently serves as a Partner Emeritus and a member of its Distinguished Executive Council. Since August 2014, Mr. Diaz has served as a Partner at Guidon Partners LP, a private investment partnership. He served as Executive Vice Chairman of Kindred Healthcare, Inc. (“Kindred” ("Cardinal"), a post-acute provider in the United States, which includes transitional careglobal integrated healthcare services and rehabilitation hospitals, sub-acute units, and home healthcare and hospice agencies, from March 2015 to March 2016, CEO from January 2004 to March 2015, President from January 2002 to May 2012 and COO from January 2002 to December 2003.products company, since September 2022. Prior to joining Kindred,his appointment as CEO, Mr. Diaz wasHollar served as Chief Financial Officer for Cardinal from May 2020 to September 2022, where he led financial activities across the Managing Member of Falcon Capital Partners, LLC, a private investmententerprise including financial strategy, capital deployment, treasury, tax, investor relations, accounting and consulting firm, andreporting. Prior to Cardinal, from 1996 to July 1998,June 2018 until April 2020, Mr. DiazHollar served in various executive capacities, including as Executive Vice President and COO, with Mariner Health Group,Chief Financial Officer of Tenneco Inc. ("Tenneco"), a national providerglobal automotive products and services company, where he was responsible for financial planning and analysis, accounting and reporting, tax, treasury and investor relations for the company. At Tenneco, Mr. Hollar also served as Senior Vice President, Finance from June 2017 to June 2018. From October 2016 to June 2017, Mr. Hollar served as the Chief Financial Officer of long-term care facilities, rehabilitation servicesSears Holding Corporation ("Sears"), a holding company for large consumer retailers across the U.S., and institutional pharmacies.as Senior Vice President, Finance from October 2014 to October 2016. Sears filed for Chapter 11 bankruptcy in October 2018. Mr. Diaz serves onHollar is an experienced finance leader who brings to the Board more than 25 years of Trusteesfinancial and operational experience spanning the healthcare, transportation, manufacturing and retail sectors.
Former Corporate Vice President, Microsoft Health and Life Sciences Independent Director Since: 2021 Committee Service: Compliance and Quality Committee; Nominating and Governance Committee Other Public Company Boards: –Olink Holding AB (publ) (NasdaqGM: OLK)						Gregory J. Moore, M.D., Ph.D., 58, served as Corporate Vice President for Microsoft Health and Life Sciences, a division of Johns HopkinsMicrosoft Corporation ("Microsoft"), a multinational technology company that produces computer software, cloud computing services, personal computers and electronics, and other related services, from 2019 to April 2023, where he led Microsoft's health and life sciences research and product development portfolio. Prior to Microsoft, Dr. Moore served as Vice President of Google Inc. ("Google"), a multinational technology company that specializes in Internet-related products and services, from 2016 to 2019, and was the founder and leader of Google Cloud Healthcare and Life Sciences globally. Dr. Moore is an engineer, practicing physician, and experienced educator. He is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, a regional healthcare provider, where he was also Director of the Institute of Advanced Application. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. Mr. Diaz formerlySince April 2023, Dr. Moore has served as a director of Olink Holding AB, a biotechnology company focused on proteomics. From 2019 until its merger with Baxter International Inc. in 2021, Dr. Moore was a member of the Board of Directors of PharMerica Corporation, Kindred,Hill-Rom Holdings, Inc., a medical technology provider. Dr. Moore brings to the Federation of American Hospitals and the Bloomberg School of Public Health at John Hopkins University. Mr. Diaz is an experienced business leader with significantBoard substantial experience in the healthcare industrymedical field as a practitioner and bringshas a deep understanding ofunique perspective, having also worked in the operational, financial and regulatory aspects of our industry and business.high technology sector for the last several years.

13

---

Table of Contents

Former Executive Vice President, Chief Financial Officer and Chief Enterprise Risk Officer, Aetna, Inc. Director Since: 2020 Independent Committee Service: Audit Committee, Chair; Nominating and Governance Committee Other Public Company Boards: —TriNet Group, Inc. (NYSE: TNET)

Shawn M. Guertin, 57, served in various roles during his tenure at Aetna, Inc. ("Aetna"), a diversified health care benefits company, including as Executive Vice President, Chief Financial Officer ("CFO") and Chief Enterprise Risk Officer from January 2014 to May 2019 and as Senior Vice President, CFO and Chief Enterprise Risk Officer from February 2013 to January 2014, where he oversaw a period of significant growth, leading to Aetna’s eventual merger with CVS Health Corporation. He also served as Head of Business Segment Finance at Aetna from April 2011 to February 2013. Prior to joining Aetna, from 1998 to 2011, Mr. Guertin served in various roles at Coventry Health Care, Inc. ("Coventry"), a diversified managed healthcare company, including as CFO and Treasurer. Prior to Coventry, Mr. Guertin held various leadership positions at The Travelers and UnitedHealthcare. Since January 2020, Mr. Guertin has served on the Board of Directors of TriNet Group, Inc., a leading provider of comprehensive human resources solutions. Mr. Guertin is an experienced business leader with significant experience in the healthcare industry and brings a deep understanding of the operational, financial and regulatory aspects of our industry and business.

Former General Partner, New Enterprise Associates Independent Director Since: Since: 2000 Independent Committee Service: Audit Committee; Compensation Committee; Nominating and Governance Committee Other Public Company Boards: –CVRx, Inc. (NASDAQ: CVRX)

John M. Nehra, 72,74, was, from 1989 until his retirement in August 2014, affiliated with New Enterprise Associates (“NEA”), a venture capital firm, including, from 1993 until his retirement, as General Partner of several of its affiliated venture capital limited partnerships. After his retirement in August 2014, Mr. Nehra remained a retired Special Partner with NEA and continued serving on the board of directors of a number of NEA’s portfolio companies. Mr. Nehra also served as Managing General Partner of Catalyst Ventures, an affiliate of NEA, from 1989 to 2013. Since 2021, Mr. Nehra has served as a member of the Board of CVRx, Inc., a commercial-stage medical device company. Mr. Nehra is an experienced business leader with approximately 45 years of experience in investment banking, research and capital markets and he brings a deep understanding of our business and industry through his nearly 2123 years of service as a member of the Board as well as significant experience in the healthcare industry through his involvement with NEA’s healthcare-related portfolio companies.

14

Notice of 2021 Annual Meeting and Proxy Statement

---

Table of Contents

Proxy Statement

Former Executive Vice President and CFO, Macy's Inc. Director Since: 2020 Independent Committee Service: Audit Committee; Compliance and Quality Committee Other Public Company Boards: —Bristol-Myers Squibb Company (NYSE: BMY) —Accenture plc (NYSE: ACN) —Western Digital Corporation (NASDAQ: WDC)

Paula A. Price, 59, most recently served as an advisor to Macy's Inc., an omni-channel retailer of merchandise, from June 2020 to November 2020, and as Executive Vice President and CFO from July 2018 to May 2020. From 2014 to 2018, Ms. Price was a full-time senior lecturer at Harvard Business School in the Accounting and Management department. From 2009 to 2014, Ms. Price served as Executive Vice President and CFO of Ahold USA, a U.S. grocery retailer. From 2006 to 2008, Ms. Price was Senior Vice President, Controller and Chief Accounting Officer ("CAO") at CVS Caremark Corporation. Earlier in her career, Ms. Price was the CFO of the Institutional Trust Services division of JPMorgan Chase & Co. and also held senior management positions at Prudential Insurance Co. of America, Diageo plc, Kraft Foods Inc., and Sears Roebuck & Company. A certified public accountant, she began her career at Arthur Andersen & Co. Since September 2020, Ms. Price has served as a member of the Board of Directors of Bristol-Myers Squibb Company, a global biopharmaceutical company ("Bristol-Myers"), and since May 2014, has been a member of the Board of Directors of Accenture plc, a professional services company. Ms. Price also rejoined the Board of Directors of Western Digital Corporation, a developer, manufacturer and provider of data storage devices and solutions, in June 2020 after serving on its Board of Directors from 2014 to 2019. She also previously served as a director of Dollar General Corporation, a large U.S. discount retailer, from 2014 to 2018. Ms. Price brings significant leadership experience in the areas of accounting, finance, general management and strategy, as well as an understanding of the healthcare industry. With her service as a director on the boards of other large public companies, Ms. Price also brings significant experience in corporate governance and executive compensation related matters.

Chief Executive Officer, DaVita Inc. Director Since: Since: 2019 Other Public Company Boards: —–Gilead Sciences, Inc. (NASDAQ: GILD)				Javier J. Rodriguez, 50,52, has served as our CEO since June 2019. From March 2014 until June 2019, he served as the CEO of DaVita Kidney Care. Since joining the Company in 1998, Mr. Rodriguez has served in a number of different capacities. From February 2012 to March 2014, he served as our President. From April 2006 through February 2012, he served as our Senior Vice President. Before that, from 2000 to 2006 he served as a Vice President of Operations and Payor Contracting. Mr. Rodriguez joined the Company in 1998 as a Director of Value Management. Prior to joining the Company, Mr. Rodriguez worked for Baxter Healthcare Corporation in Finance from 1995 to 1996. He also previously served as Director of Operations for CBS Marketing Inc. in Mexico City. Since June 2020, Mr. Rodriguez has been a member of the Board of Directors of Gilead Sciences, Inc., a research-based pharmaceutical company. Mr. Rodriguez provides extensive knowledge of our industry, business, regulatory environment and operations as well as significant executive leadership and management experience.
President, Chief Executive Officer and Chairman of the Board, Labcorp Independent Director Since: 2022 Committee Service: Audit Committee; Compliance and Quality Committee Other Public Company Boards: –Labcorp (NYSE: LH)						Adam H. Schechter, 58, has served as Chairman of the Board of Labcorp, a leading global life sciences company, since May 2020, as a director of Labcorp since April 2013, and President and Chief Executive Officer since November 2019. Mr. Schechter previously served as special advisor to the CEO of Merck & Co., Inc. (“Merck”), a multinational pharmaceutical company, from January 2019 to July 2019. From 2010 to 2018, Mr. Schechter was an Executive Vice President of Merck, where he was a member of Merck’s executive committee, pharmaceutical and vaccines operating committee, and President of Merck’s Global Human Health Division, which included Merck’s worldwide pharmaceutical and vaccine businesses. Prior to becoming President, Global Human Health, Mr. Schechter served as President, Global Pharmaceutical Business of Merck from 2007 to 2010. In 2022, Mr. Schechter earned the CERT Certificate in Cybersecurity Oversight. Mr. Schechter brings to the Board extensive knowledge of the healthcare industry, operations and regulatory environment, significant executive leadership and management experience. In addition, his CERT Certificate in Cybersecurity Oversight strengthens this valuable expertise of the Board.

15
			Notice of 2023 Annual Meeting and Proxy Statement			4

Advisory Partner, Bain & Company, Inc. Independent Director Since: 2016 Independent Committee Service: Service: Nominating and Governance Committee, Chair; Compliance and Quality Committee Other Public Company Boards: —–Bristol-Myers Squibb Company (NYSE: BMY)						Phyllis R. Yale, 63,65, has been an Advisory Partner with Bain & Company, Inc. (“Bain”), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and was a leader in building Bain’s healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world’s leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol-Myers.Bristol-Myers Squibb Company, a global biopharmaceutical company, and since 2014 has served as a member of the Board of Directors of Blue Cross Blue Shield of Massachusetts ("BCBS MA"). Ms. Yale previously served as Chair of the BCBS MA Board of Directors from 2014 to 2019 and Chair of the Board of Directors of Kindred and Chair of Blue Cross Blue Shield of Massachusetts, and has been on the board of directors of various other public, non-profit and privately held corporations.Healthcare, Inc. from 2010 to 2018. Ms. Yale has a deep knowledge base in the U.S. healthcare sector and has experience in severalmany aspects of the healthcare industry, including corporate strategies, marketing and cost and quality management, as well as mergers and acquisitions.

named nominees as directors.

16

Notice of 2021 Annual Meeting and Proxy Statement

director nominees.

			Notice of 2023 Annual Meeting and Proxy Statement			6

TableSelection of Contents

Directors

Independent, Female Board Chair

Three Out of Four of Our Current Committee Chairs are DiverseDiverse*

Pamela Arway Independent Board Chair

Barbara Desoer Chair, Compensation Committee

Paul Diaz** Chair, Compliance & Quality Committee

Jason M. Hollar Chair, Audit Committee

Phyllis Yale

Barbara Desoer

Paul Diaz

Shawn Guertin

Independent Board Chair

Chair, Nominating & Governance Committee

Chair, Compensation Committee

Chair, Compliance & Quality Committee

Chair, Audit Committee

18

Notice of 2021 Annual Meeting and Proxy Statement

Table*Director Nominees Diversity and Tenure calculations are as of Contents

Stockholder Director Recommendations

Experience and Skills
Risk Management			Notice of 2023 Annual Meeting and Proxy Statement			8

Gov’t/Regulatory/Public Policy

DIRECTOR NOMINEE SKILLS MATRIX

CEO ExperienceSKILLS AND EXPERIENCE

Arway

Berg

Desoer

Hollar

Moore

Nehra

Rodriguez

Schechter

Yale

InternationalStrategic Initiatives /  M&A

☑

☑

☑

☑

☑

☑

☑

☑

8

Risk Management

☑

☑

☑

☑

☑

☑

☑

7

Finance / Capital  Allocation / Accounting

☑

☑

☑

☑

☑

☑

☑

7

Tech / Digital  Transformation /  Cybersecurity

☑

☑

☑

3

Gov't / Regulatory /  Public Policy

☑

☑

☑

☑

☑

5

Public Co. Board ExperienceCEO

☑

☑

☑

3

HealthcareHuman Capital Mgmt / Compensation

☑

☑

☑

☑

☑

☑

☑

☑

8

Healthcare Provider / Payor / Investing / VC

☑

☑

☑

☑

☑

☑

☑

7

Public Co. Corporate  Governance

☑

☑

☑

☑

☑

☑

☑

☑

☑

9

Table of Contents

The Board is committed to continuous improvement and annual self-evaluations are an important tool to that end. In 2020, we enhanced ourOur Board and Committee evaluation process to includeincludes both written questionnaires and live interviews with directors on a rotating cycle, an overview of which is set forth below.

Director Independence
			Rotating cycle with anonymous written evaluations each year and live interviews with each director every other year, which includes individual director evaluations.   Process is overseen by the Nominating and Governance Committee.
			Directors provide feedback regarding performance and effectiveness of the Board and its Committees, the Chair and, every other year, individual director performance.
			The Board reviews the results of these evaluations in executive session.   The Chair of the Board speaks with each director for one-on-one discussion, as appropriate.
			Follow-up items are addressed at subsequent Board or Committee meetings, as appropriate, and Committee actions are reported back to the full Board. The Nominating and Governance Committee considers the effectiveness of the self-evaluation process on an annual basis.

			Notice of 2023 Annual Meeting and Proxy Statement			10

entities (active or passive), the level of involvement by the director or executive officer as a partner in any such director-affiliated entities, any special arrangements or relationships between the parties that would lead to a personal benefit, any personal benefits derived as a result of business relationships with the Company, any other personal benefit derived by any director or executive officer as a result of the disclosed relationships or any other relevant factors.

Under the NYSE Independence Standards, a director is deemed not independent if the director is or has been employed by the Company within the last three years or if the director has received, during any twelve-month period within the last three years, more than $120,000 in direct compensation from the listed company, other than director and committee fees. Under the Additional Independence Standards, a director is deemed not independent if (i) within the last four calendar years, (a) the director was an employee of the Company or one of its wholly-owned subsidiaries or (b) an immediate family member of the director was an executive officer of the Company, (ii) the director, during the current calendar year or any of the three immediately preceding calendar years has been paid by the Company more than $120,000 in compensation for services, other than for services rendered as a director, or (iii) the director is employed as an executive officer of another public company on whose board of directors any of the Company’s current executive officers serve.

20

Notice of 2021 Annual Meeting and Proxy Statement

---

Table of Contents

The Board has determined that all of the director nominees, other than Messrs.Mr. Rodriguez, and Berg, as well as each other individual who served as a director at any time during 2020, other than Mr. Thiry,2022, are independent under the NYSE Independence Standards and under our Additional Independence Standards.

TableLeadership Structure and Meetings of Contents

Effective June 1, 2020, the Board appointed Independent Directors

The Board believes that this leadership structure is appropriate for the Company at this time because it allows for independent oversight of management, increases management accountability, and encouragesfacilitates an objective evaluation of management’s performance relative to compensation. The independent directors evaluate the Board’s leadership structure, typically on an annual basis.

22

Notice of 2021 Annual Meeting and Proxy Statement

---

Table of Contents

23
			Notice of 2023 Annual Meeting and Proxy Statement			12

ESG Areas of Focus

Patient Care

Teammate Engagement

Environmental Stewardship

Healthy Communities

Leading with Integrity and Accountability

●

–Quality of Care ●–Patient Experience ●–Patient Education ●–Health Equity

● –Diversity & Belonging ●–Teammate Development ●–The DaVita Way

● –Carbon Emissions Reduction ●–Water & Waste Reduction

● –Charitable Giving ●–Volunteerism

● –Compliance, Ethics & Governance ●–Data Privacy ●–Supply Chain

24
			–7,800+DaVita patients received a kidney transplant
			–Peritoneal dialysis (PD) and home hemodialysis (HHD) patients increasingly used connected cyclers and DaVita's patented technology, DaVita Care Connect®, enabling more convenient access to home treatment data and two-way communication with their care team
			–We largely see similar outcomes across race in core clinical metrics such as hospitalizations, readmissions and infection rates in our U.S. outpatient dialysis centers
			–33,600+ people participated in a Kidney Smart class, our kidney disease education program

			–38,000+teammates are a part of DaVita's new career pathways program, Clinical Ladders
			–Our overall U.S. teammate population is comprised of 78% women and 56%people of color as of December 31, 2022
			–1,450+ teammates were pursuing or received their nursing degree, funded by DaVita, as part of our Bridge to Your Dreams program
			–16,000+ teammates participated in a DaVita University professional development course

			–We are committed to net zero carbon emissions by 2050 as part of the White House/HHS Climate Sector Pledge
			–Our virtual power purchase agreements produce enough renewable energy to power 100%of our U.S. operations
			–We designed and built our first net zero dialysis clinic, powered by solar energy
			–382 clinics received energy efficient LED lighting upgrades